Current strategies for treatment of relapsed/refractory multiple myeloma

被引：69

作者：

Laubach, Jacob P. ^{[1
]}

Voorhees, Peter M. ^{[2
]}

Hassoun, Hani ^{[3
]}

Jakubowiak, Andrzej ^{[4
,5
]}

Lonial, Sagar ^{[6
]}

Richardson, Paul G. ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, Boston, MA 02115 USA

[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Div Hematol Oncol, Chapel Hill, NC 27599 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA

[4] Univ Chicago, Dept Med, Chicago, IL 60637 USA

[5] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA

[6] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA USA

来源：

EXPERT REVIEW OF HEMATOLOGY | 2014年 / 7卷 / 01期

关键词：

autologous stem cell transplantation; bortezomib; carfilzomib; clonal evolution; elotuzumab; lenalidomide; multiple myeloma; pomalidomide; STEM-CELL TRANSPLANTATION; LOW-DOSE DEXAMETHASONE; LENALIDOMIDE PLUS DEXAMETHASONE; PROTEASOME INHIBITOR MLN9708; RANDOMIZED PHASE-III; BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE; PEGYLATED LIPOSOMAL DOXORUBICIN; IMPAIRED RENAL-FUNCTION; HIGH-RISK PATIENTS; PERIPHERAL NEUROPATHY;

D O I：

10.1586/17474086.2014.882764

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In spite of significant advances in the management of multiple myeloma (MM), the disease remains incurable and nearly all patients ultimately relapse and require salvage chemotherapy. As such, relapsed and relapsed-refractory MM remains a critical area of research pertaining to biological mechanisms of progression and chemotherapy resistance, as well as to the development of new pharmacologic agents and immunologic approaches for the disease. The immunomodulatory agents and proteasome inhibitors represent the cornerstone of treatment in this setting, with combination regimens incorporating these drugs demonstrating encouraging rates and duration of response, including the newer agents, pomalidomide and carfilzomib. In addition, novel drug classes have shown promising activity in RR MM, including the orally-administered proteasome inhibitors ixazomib and oprozomib; monoclonal antibodies such as the anti-CS1 monoclonal antibody elotuzumab and anti-CD38 monoclonal antibody daratumumab; and histone deacetylase inhibitors such as panobinostat and rocilinostat.

引用

页码：97 / 111

页数：15

共 128 条

[91] Extended follow-up of a phase 3 trial in relapsed multiple myeloma:: final time-to-event results of the APEX trial [J].

Richardson, Paul G. ;

Sonneveld, Pieter ;

Schuster, Michael ;

Irwin, David ;

Stadtmauer, Edward ;

Facon, Thierry ;

Harousseau, Jean-Luc ;

Ben-Yehuda, Dina ;

Lonial, Sagar ;

Goldschmidt, Hartmut ;

Reece, Donna ;

Miguel, Jesus San ;

Blade, Joan ;

Boccadoro, Mario ;

Cavenagh, Jamie ;

Alsina, Melissa ;

Rajkumar, S. Vincent ;

Lacy, Martha ;

Jakubowiak, Andrzej ;

Dalton, William ;

Boral, Anthony ;

Esseltine, Dixie-Lee ;

Schenkein, David ;

Anderson, Kenneth C. .

BLOOD, 2007, 110 (10) :3557-3560

[92] A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma [J].

Richardson, Paul G. ;

Blood, Emily ;

Mitsiades, Constantine S. ;

Jagannath, Sundar ;

Zeldenrust, Steven R. ;

Alsina, Melissa ;

Schlossman, Robert L. ;

Rajkumar, S. Vincent ;

Desikan, K. Raman ;

Hideshima, Teru ;

Munshi, Nikhil C. ;

Kelly-Colson, Kathleen ;

Doss, Deborah ;

McKenney, Mary L. ;

Gorelik, Svetlana ;

Warren, Diane ;

Freeman, Andrea ;

Rich, Rebecca ;

Wu, Anfang ;

Olesnyckyj, Marta ;

Wride, Kenton ;

Dalton, William S. ;

Zeldis, Jerome ;

Knight, Robert ;

Weller, Edie ;

Anderson, Kenneth C. .

BLOOD, 2006, 108 (10) :3458-3464

[93] Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib [J].

Richardson, Paul G. ;

Briemberg, Hannah ;

Jagannath, Sundar ;

Wen, Patrick Y. ;

Barlogie, Bart ;

Berenson, James ;

Singhal, Seema ;

Siegel, David S. ;

Irwin, David ;

Schuster, Michael ;

Srkalovic, Gordan ;

Alexanian, Raymond ;

Rajkumar, S. Vincent ;

Limentani, Steven ;

Alsina, Melissa ;

Orlowski, Robert Z. ;

Najarian, Kevin ;

Esseltine, Dixie ;

Anderson, Kenneth C. ;

Amato, Anthony A. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (19) :3113-3120

[94] PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma [J].

Richardson, Paul G. ;

Schlossman, Robert L. ;

Alsina, Melissa ;

Weber, Donna M. ;

Coutre, Steven E. ;

Gasparetto, Cristina ;

Mukhopadhyay, Sutapa ;

Ondovik, Michael S. ;

Khan, Mahmudul ;

Paley, Carole S. ;

Lonial, Sagar .

BLOOD, 2013, 122 (14) :2331-2337

[95] Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib [J].

Richardson, Paul G. ;

Siegel, David ;

Baz, Rachid ;

Kelley, Susan L. ;

Munshi, Nikhil C. ;

Laubach, Jacob ;

Sullivan, Daniel ;

Alsina, Melissa ;

Schlossman, Robert ;

Ghobrial, Irene M. ;

Doss, Deborah ;

Loughney, Nora ;

McBride, Laura ;

Bilotti, Elizabeth ;

Anand, Palka ;

Nardelli, Lisa ;

Wear, Sandra ;

Larkins, Gail ;

Chen, Min ;

Zaki, Mohamad H. ;

Jacques, Christian ;

Anderson, Kenneth C. .

BLOOD, 2013, 121 (11) :1961-1967

[96] Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma [J].

Richardson, Paul G. ;

Weller, Edie ;

Lonial, Sagar ;

Jakubowiak, Andrzej J. ;

Jagannath, Sundar ;

Raje, Noopur S. ;

Avigan, David E. ;

Xie, Wanling ;

Ghobrial, Irene M. ;

Schlossman, Robert L. ;

Mazumder, Amitabha ;

Munshi, Nikhil C. ;

Vesole, David H. ;

Joyce, Robin ;

Kaufman, Jonathan L. ;

Doss, Deborah ;

Warren, Diane L. ;

Lunde, Laura E. ;

Kaster, Sarah ;

DeLaney, Carol ;

Hideshima, Teru ;

Mitsiades, Constantine S. ;

Knight, Robert ;

Esseltine, Dixie-Lee ;

Anderson, Kenneth C. .

BLOOD, 2010, 116 (05) :679-686

[97] Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma [J].

Richardson, Paul G. ;

Weller, Edie ;

Jagannath, Sundar ;

Avigan, David E. ;

Alsina, Melissa ;

Schlossman, Robert L. ;

Mazumder, Amitabha ;

Munshi, Nikhil C. ;

Ghobrial, Irene M. ;

Doss, Deborah ;

Warren, Diane L. ;

Lunde, Laura E. ;

McKenney, Mary ;

Delaney, Carol ;

Mitsiades, Constantine S. ;

Hideshima, Teru ;

Dalton, William ;

Knight, Robert ;

Esseltine, Dixie-Lee ;

Anderson, Kenneth C. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (34) :5713-5719

[98] Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy [J].

Richardson, Paul G. ;

Xie, Wanling ;

Mitsiades, Constantine ;

Chanan-Khan, Asher A. ;

Lonial, Sagar ;

Hassoun, Hani ;

Avigan, David E. ;

Oaklander, Anne Louise ;

Kuter, David J. ;

Wen, Patrick Y. ;

Kesari, Santosh ;

Briemberg, Hannah R. ;

Schlossman, Robert L. ;

Munshi, Nikhil C. ;

Heffner, L. Thompson ;

Doss, Deborah ;

Esseltine, Dixie-Lee ;

Weller, Edie ;

Anderson, Kenneth C. ;

Amato, Anthony A. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (21) :3518-3525

[99] Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline [J].

Richardson, Paul G. ;

Sonneveld, Pieter ;

Schuster, Michael W. ;

Stadtmauer, Edward A. ;

Facon, Thierry ;

Harousseau, Jean-Luc ;

Ben-Yehuda, Dina ;

Lonial, Sagar ;

Goldschmidt, Hartmut ;

Reece, Donna ;

Blade, Joan ;

Boccadoro, Mario ;

Cavenagh, Jamie D. ;

Boral, Anthony L. ;

Esseltine, Dixie-Lee ;

Wen, Patrick Y. ;

Amato, Anthony A. ;

Anderson, Kenneth C. ;

San Miguel, Jesus .

BRITISH JOURNAL OF HAEMATOLOGY, 2009, 144 (06) :895-903

[100] Bortezomib or high-dose dexamethasone for relapsed multiple myeloma [J].

Richardson, PG ;

Sonneveld, P ;

Schuster, MW ;

Irwin, D ;

Stadtmauer, EA ;

Facon, T ;

Harousseau, JL ;

Ben-Yehuda, D ;

Lonial, S ;

Goldschmidt, H ;

Reece, D ;

San-Miguel, JF ;

Bladé, J ;

Boccadoro, M ;

Cavenagh, J ;

Dalton, WS ;

Boral, AL ;

Esseltine, DL ;

Porter, JB ;

Schenkein, D ;

Anderson, KC .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24) :2487-2498

← 4 5 6 7 8 9 10 11 12 13 →